Long-term Impact of Oral Azithromycin Taken by Gambian Women During Labor on Prevalence and Antibiotic Susceptibility of Streptococcus pneumoniae and Staphylococcus aureus in Their Infants: Follow-up of a Randomized Clinical Trial

Abdoulie Bojang, Bully Camara, Isatou Jagne Cox, Claire Oluwalana, Kodou Lette, Effua Usuf, Christian Bottomley, Benjamin P Howden, Umberto D'Alessandro, Anna Roca, Abdoulie Bojang, Bully Camara, Isatou Jagne Cox, Claire Oluwalana, Kodou Lette, Effua Usuf, Christian Bottomley, Benjamin P Howden, Umberto D'Alessandro, Anna Roca

Abstract

Background: Oral azithromycin given to women in labor decreases maternal and neonatal bacterial carriage but increases azithromycin-resistant bacteria during at least 4 weeks following the intervention. We assessed the prevalence of bacterial carriage and azithromycin resistance 12 months after treatment among study infants.

Methods: Nasopharyngeal swabs (NPSs) were collected between November 2014 and May 2015 from children aged 11-13 months whose mothers had received azithromycin or placebo during labor. Streptococcus pneumoniae and Staphylococcus aureus were isolated using conventional microbiological methods. Antibiotic susceptibility was determined by disk diffusion and confirmed by Etest or VITEK-2.

Results: NPSs were collected from 461 children. The prevalence of S. pneumoniae and S. aureus was similar between children from the azithromycin and placebo arms (85.0% vs 82.1%; odds ratio [OR], 1.23 [95% confidence interval {CI}, .73-2.08] for S. pneumoniae and 21.7% vs 21.3%; OR, 1.02 [95% CI, .64-1.64] for S. aureus). Prevalence of azithromycin-resistant S. pneumoniae was similar in both arms (1.8% vs 0.9% in children from the azithromycin and placebo arms, respectively; OR, 2.10 [95% CI, .30-23.38]); resistance to other antibiotics was also similar between arms. For S. aureus, there was no difference in azithromycin resistance between children in the azithromycin (3.1%) and placebo (2.6%) arms (OR, 1.22 [95% CI, .35-4.47]) or resistance to any other antibiotics.

Conclusions: The higher prevalence of S. aureus azithromycin resistance observed among women treated during labor and their babies 4 weeks after treatment had waned 12 months after delivery. Azithromycin intervention did not induce other antibiotic resistance to S. pneumoniae or S. aureus.

Clinical trials registration: NCT01800942.

Figures

Figure 1.
Figure 1.
Heat map showing pattern of Streptococcus pneumoniae isolates resistant (R) to at least 1 antibiotic (except cotrimoxazole), by arm. Resistance Etest cutoff values: azithromycin, ≥2 μg/mL; penicillin, ≥8 μg/mL; chloramphenicol, ≥8 μg/mL; erythromycin, ≥1 μg/mL; and clindamycin, ≥1 μg/mL. *Cotrimoxazole susceptibility patterns for isolates resistant to at least 1 of azithromycin, penicillin, chloramphenicol, erythromycin, and clindamycin are included in the table. Resistance cutoff value was ≤18 mm using disk diffusion.
Figure 2.
Figure 2.
Heat map showing pattern of Staphylococcus aureus isolates resistant (R) to at least 1 antibiotic, by arm. Resistance Etest cutoff values: azithromycin, ≥8 μg/mL; chloramphenicol, ≥32 μg/mL; erythromycin, ≥16 μg/mL; clindamycin, ≥4 μg/mL; cefoxitin for methicillin-resistant Staphylococcus aureus (MRSA), ≥8. Intermediate Etest cutoff values: azithromycin, 4 μg/mL; erythromycin, 1–4 μg/mL.

References

    1. Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014; 143:225–45.
    1. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:422–6.
    1. Harding-Esch EM, Sillah A, Edwards T et al. ; Partnership for Rapid Elimination of Trachoma (PRET) Study Group Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis 2013; 7:e2115.
    1. Yohannan J, Munoz B, Mkocha H et al. . Can we stop mass drug administration prior to 3 annual rounds in communities with low prevalence of trachoma? PRET Ziada trial results. JAMA Ophthalmol 2013; 131:431–6.
    1. Gebre T, Ayele B, Zerihun M et al. . Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster-randomised trial. Lancet 2012; 379:143–51.
    1. Schémann JF, Guinot C, Traore L et al. . Longitudinal evaluation of three azithromycin distribution strategies for treatment of trachoma in a sub-Saharan African country, Mali. Acta Trop 2007; 101:40–53.
    1. Lee JS, Muñoz BE, Mkocha H, Gaydos CA, Quinn TC, West SK. The effect of multiple rounds of mass drug administration on the association between ocular Chlamydia trachomatis infection and follicular trachoma in preschool-aged children. PLoS Negl Trop Dis 2014; 8:e2761.
    1. Biebesheimer JB, House J, Hong KC et al. . Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. Ophthalmology 2009; 116:2047–50.
    1. Burr SE, Milne S, Jafali J et al. . Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia. Bull World Health Organ 2014; 92:490–8.
    1. Porco TC, Gebre T, Ayele B et al. . Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA 2009; 302:962–8.
    1. Luntamo M, Kulmala T, Cheung YB, Maleta K, Ashorn P. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. Trop Med Int Health 2013; 18:386–97.
    1. Unger HW, Ome-Kaius M, Wangnapi RA et al. . Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial. BMC Med 2015; 13:9.
    1. Coles CL, Mabula K, Seidman JC et al. . Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment. Clin Infect Dis 2013; 56:1519–26.
    1. Skalet AH, Cevallos V, Ayele B et al. . Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med 2010; 7:e1000377.
    1. Haug S, Lakew T, Habtemariam G et al. . The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 2010; 51:571–4.
    1. Bojang E, Jafali J, Perreten V et al. . Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control. BMC Microbiol 2017; 17:75.
    1. Unger HW, Aho C, Ome-Kaius M et al. . Impact of intermittent preventive treatment in pregnancy with azithromycin-containing regimens on maternal nasopharyngeal carriage and antibiotic sensitivity of Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus: a cross-sectional survey at delivery. J Clin Microbiol 2015; 53:1317–23.
    1. Oluwalana C, Camara B, Bottomley C et al. . Azithromycin in labor lowers clinical infections in mothers and newborns: a double-blind trial. Pediatrics 2017; 139. doi:10.1542/peds.2016-2281.
    1. Burr SE, Camara B, Oluwalana C et al. . Does azithromycin given to women in labour decrease ocular bacterial infection in neonates? A double-blind, randomized trial. BMC Infect Dis 2017; 17:799.
    1. Roca A, Oluwalana C, Bojang A et al. . Oral azithromycin given during labour decreases bacterial carriage in the mothers and their offspring: a double-blind randomized trial. Clin Microbiol Infect 2016; 22:565.e1–9.
    1. Roca A, Oluwalana C, Camara B et al. . Prevention of bacterial infections in the newborn by pre-delivery administration of azithromycin: study protocol of a randomized efficacy trial. BMC Pregnancy Childbirth 2015; 15:302.
    1. O’Brien KL, Nohynek H; World Health Organization Pneumococcal Vaccine Trials Carriage Working Group Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 2003; 22:e1–11.
    1. Clinical Laboratory and Standards Institute. Performance standards for antimicrobial susceptibility testing. 27th ed. Wayne, PA: CLSI, 2017:224.
    1. Steward CD, Raney PM, Morrell AK et al. . Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J Clin Microbiol 2005; 43:1716–21.
    1. Batt SL, Charalambous BM, Solomon AW et al. . Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47:2765–9.
    1. Ho DK, Sawicki C, Grassly N. Antibiotic resistance in Streptococcus pneumoniae after azithromycin distribution for trachoma. J Trop Med 2015; 2015:917370.
    1. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482–92.
    1. Hill PC, Onyeama CO, Ikumapayi UN et al. . Bacteraemia in patients admitted to an urban hospital in West Africa. BMC Infect Dis 2007; 7:2.
    1. Senghore M, Bayliss SC, Kwambana-Adams BA et al. . Transmission of Staphylococcus aureus from humans to green monkeys in The Gambia as revealed by whole-genome sequencing. Appl Environ Microbiol 2016; 82:5910–7.
    1. Seidman JC, Coles CL, Silbergeld EK et al. . Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Int J Epidemiol 2014; 43:1105–13.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir